Osteopetroses and immunodeficiencies in humans

Current Opinion in Allergy and Clinical Immunology

Volumn 6, Issue 6, 2006, Pages 421-427

  Villa, Anna ^a,b   Vezzoni, Paolo ^a   Frattini, Annalisa ^a  

^a CNR   (Italy)

^b NONE   (Italy)

Author keywords

Osteoclast differentiation; Osteoimmunology; Osteopetrosis

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; TUMOR NECROSIS FACTOR;

ALBERS SCHOENBERG DISEASE; CELL DIFFERENTIATION; CELL FUNCTION; CELL TYPE; DENDRITIC CELL; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPETENT CELL; LYMPHOCYTE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; BONE RESORPTION; CELL ADHESION MOLECULES; CELL DIFFERENTIATION; DENDRITIC CELLS; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNITY, NATURAL; IMMUNOLOGIC DEFICIENCY SYNDROMES; LYMPHOCYTES; MICE; MICE, KNOCKOUT; OSTEOCLASTS; OSTEOPETROSIS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B;

EID: 33750798325     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/01.all.0000246620.26623.5b     Document Type: Review

References (61)

1. Horowitz MC, Lorenzo JC. The origin of osteoclasts. Curr Opin Rheumatol 2004; 16:464-468.
2. Jimi E, Ghosh S. Role of nuclear factor κB in the immune system and bone. Immunol Rev 2005; 208:80-87. A comprehensive review describing signalling pathway leading to NF-κB activation and their role in osteoclast differentiation.
3. Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signalling in osteoclastogenesis and bone disease. Trends Mol Med 2006; 12:17-25. This paper describes the molecular cross talk between RANK and RANKL, and the main factors involved in osteoclastogenesis.
4. Helfrich MH, Gerritsen EJ. Formation of nonresorbing osteoclasts from peripheral blood mononuclear cells of patients with malignant juvenile osteopetrosis. Br J Haematol 2001; 112:64-68.
5. Sato K, Takayanagi H. Osteoclasts, rheumatoid arthritis, and osteoimmunology. Curr Opin Rheumatol 2006; 18:419-426. A complete recent review describing a full scenario linking osteoclasts to the hematopoietic system.
6. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 307:315-323.
7. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423:337-342.
8. Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet 2003; 4:638-649.
9. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12:1260-1268.
10. Dougall WC, Glaccum M, Charrier K, et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999; 13:2412-2424.
11. Rho J, Takami M, Choi Y. Osteoimmunology: interactions of the immune and skeletal systems. Mol Cell 2004; 17:1-9.
12. Lomaga MA, Yeh WC, Sarosi I, et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40 and LPS signalling. Genes Dev 1999; 13:1015-1024.
13. Wada T, Nakashima T, Oliveira-dos-Santos AJ, et al. The molecular scaffold Gab2 is a crucial component of RANK signalling and osteoclastogenesis. Nat Med 2005; 11:394-399. The authors identify for the first time a class of molecular scaffolds acting as key mediator of RANK induced osteoclastogenesis which has a crucial role in osteoclast differentiation.
14. Wagner EF, Eferl R. Fos/AP-1 proteins in bone and the immune system. Immunol Rev 2005; 28:126-140. In the present review, the authors focus on Fos/AP1 factors which play a crucial role in inflammatory bone loss by regulating NFATc1 and interferon system.
15. Franzoso G, Carlson L, Xing L, et al. Requirement for NF-kappa B in osteoclast and B-cell development. Genes Dev 1997; 11:3482-3496.
16. Grigoriadis AE, Wang ZQ, Cecchini MG, et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 1994; 266:443-448.
17. Takayanagi H, Kim S, Matsuo K, et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon beta. Nature 2002; 416:744-749.
18. Takayanagi H, Kim S, Koga T, et al. Induction and activation of the transcription NFATc1(NFAT2) integrate RANKL signalling in terminal differentiation of osteoclasts. Dev Cell 2002; 3:889-901.
19. Ghosh S, May MJ, Kopp EB. NF-κB and rel proteins: evolutionary conserved mediators of immune responses. Annu Rev Immunol 1998; 16:225-260.
20. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol 2000; 18:621-663.
21. Hu Y, Baud V, Delhase M, et al. Abnormal morphogenesis but intact IKK activation in mice lacking the IKK-alpha subunit of I-kappa-B kinase. Science 1999; 284:316-320.
22. Chen ZJ. Ubiquitin signalling in the NF-κB pathway. Nat Cell Biol 2005; 7:758-765. The ubiquitin proteosome pathway is crucial for NF-κB activation. This report summarizes the current view of this signal in canonical and non canonical pathways.
23. Wang C, Deng L, Hong M, et al. TAK1 is a ubiquitin dependent kinase of MKK and IKK. Nature 2001; 412:346-351.
24. Morlon A, Munnich A, Smashi A. TAB2, TRAF6 and TAK1 are involved in NF-κB activation induced by the TNF-receptor, Edar and its adaptator Edaradd. Hum Mol Genet 2005; 14:3751-3757.
25. Headon DJ, Emmal SA, Ferguson BM, et al. Gene defect in ectodermal dysplasia implicates a death domain adapter in development. Nature 2001; 414:913-916.
26. Courtois G, Smahi A. NF-kappaB-related genetic diseases. Cell Death Differ 2006; 13:843-851. Incontinentia pigmenti, anhidrotic ectodermal dysplasia with immunodeficiency and cylindromatosis are genetic defects due to different mutations affecting NFkappaB. This review extensively analyses these inherited disorders.
27. Smahi A, Courtois G, Vabres P, et al. Genomic rearrangement in NEMO impairs NF-κB activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium. Nature 2000; 405:466-472.
28. Zonana J, Elder ME, Schneider LC, et al. A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO). Am J Hum Genet 2000; 67:1555-1562.
29. Doffinger R, Smahi A, Bessia C, et al. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-κB signalling. Nat Genet 2001; 27:277-285.
30. Jain A, Ma CA, Liu S, et al. Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia. Nat Immunol 2001; 2:223-228.
31. Niehues T, Reichenbach J, Neubert J, et al. Nuclear factor kappaB essential modulator-deficient child with immunodeficiency yet without anhidrotic ectodermal dysplasia. J Allergy Clin Immunol 2004; 114:1456-1462.
32. Orange JS, Levy O, Brodeur SR, et al. Human nuclear factor kappa B essential modulator mutation can result in immunodeficiency without ectodermal dysplasia. J Allergy Clin Immunol 2004; 111:650-656.
33. Humphrey MB, Lanier LL, Nakamura MC. Role of ITAM-containing adapter proteins and their receptors in the immune system and bone. Immunol Rev 2005; 208:50-65. By the analysis of mice lacking DAP12 and FcRγ, the authors describe the role of these molecules in osteoclast and myeloid lineages.
34. Monroe JG. ITAM-mediated tonic signalling through pre-BCR and BCR complexes. Nat Rev Immunol 2006; 6:283-294.
35. Kim N, Takami M, Rho J, et al. A novel member of the leukocyte receptor complex regulates osteoclast differentiation. J Exp Med 2002; 195:201-209.
36. Koga T, Inui M, Inoue K, et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 2004; 428:758-763.
37. Takayanagi H. Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med 2005; 83:170-179. In this review, the author describes the molecular and biochemical basis of cross talk between bone and immune system.
38. Paloneva J, Kestila M, Wu J, et al. Loss of function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts. Nat Genet 2000; 25:357-361.
39. Paloneva J, Mandelin J, Kiialainen A, et al. DAP12/TREM2 deficiency results in impaired osteoclasts differentiation and osteoeporotic features. J Exp Med 2003; 198:656-662.
40. Cella M, Buonsanti C, Strader C, et al. Impaired differentiation of osteoclasts in TREM2 deficient individuals. J Exp Med 2003; 198:645-651.
41. Colonna M. DAP12 signaling: from immune cells to bone modeling and brain myelination. J Clin Invest 2003; 111:313-314.
42. Tomasello E, Desmoulins PO, Chemin K, et al. Combined natural killer cell and dendritic cell functional deficiency in KARAP/DAP12 loss-of-function mutant mice. Immunity 2000; 13:355-364.
43. Bakker AB, Hoek RM, Cerwenka A, et al. DAP12-deficient mice fail to develop autoimmunity due to impaired antigen priming. Immunity 2000; 13:345-353.
44. Kaifu T, Nakahara J, Inui M, et al. Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in DAP12-deficient mice. J Clin Invest 2003; 111:323-332.
45. Nataf S, Anginot A, Vuaillat C, et al. Brain and bone damage in KARAP/DAP12 loss-of-function mice correlate with alterations in microglia and osteoclast lineages. Am J Pathol 2005; 166:275-286.
46. Mocsai A, Humphrey MB, Van Ziffle JA, et al. The immunomodulatory adapter proteins DAP12 and Fc receptor gamma chain (FcRgamma) regulate development of functional osteoclasts through Syk tyrosine kinase. Proc Natl Acad Sci USA 2004; 101:6158-6163.
47. Takegahara N, Takamatsu H, Toyofuku T, et al. Plexin-A1 and its interaction with DAP12 in immune responses and bone homeostasis. Nat Cell Biol 2006; 8:615-622. This papers couples the semaphorins and their plexin receptors to the ITAM pathway.
48. Arron JR, Choi Y. Bone versus immune system. Nature 2000; 408:535-536.
49. Kollet O, Dar A, Shivtiel S, et al. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med 2006; 12:657-664. This paper demonstrates that bone resorbing osteoclasts trigger proliferation of immature bone marrow progenitors. This observation represents the first evidence that osteoblast/osteoclast balance is the major regulator of hematopoiesis and turnover of the endosteal stem cell niche.
50. Yoshida H, Hayashi S, Kunisada T, et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 1990; 345:442-444.
51. Gu H, Saito K, Lori D, et al. Essential role for Gab2 in the allergic response. Nature 2001; 412:186-190.
52. Kobayashi T, Walsh PT, Walsh MC, et al. TRAF6 is a critical factor for dendritic cell maturation and development. Immunity 2003; 19:353-363.
53. Iotsova V, Caamano J, Loy J, et al. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 1997; 3:1285-1289.
54. Sha WC, Liou HC, Tuomanen EI, Baltimore D. Targeted disruption of the p50 subunit of NF-kappa-B leads to multifocal defects in immune responses. Cell 1995; 80:321-330.
55. Claudio E, Brown K, Park S, et al. BAFF-induced NEMO-independent processing of NF-kappa-B2 in maturing B cells. Nat Immunol 2002; 3:958-965.
56. Tondravi MM, McKercher SR, Anderson K, et al. Osteopetrosis in mice lacking haematopoietic transcription factor PU.1. Nature 1997; 386:81-84.
57. Li Q, Van Antwerp D, Mercurio F, et al. Severe liver degeneration in mice lacking the I-kappa-B kinase 2 gene. Science 1999; 284:321-325.
58. Rudolph D, Yeh WC, Wakeham A, et al. Severe liver degeneration and lack of NF-kappa-B activation in NEMO/IKK-gamma-deficient mice. Genes Dev 2000; 14:854-862.
59. Takai T, Li M, Sylvestre D, et al. FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell 1994; 76:519-529.
60. Turner M, Mee PJ, Costello PS, et al. Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk. Nature 1995; 378:298-302.
61. Cheng AM, Rowley B, Pao W, et al. Syk tyrosine kinase required for mouse viability and B-cell development. Nature 1995; 378:303-306.